Evidence map›Paper›PMID 39280472›Full record

ArticleCureus2024

Sero-Positive Isolated Ocular Myasthenia Gravis.

Taimoor A Khan, Muhammad Zeshan Sadiq, Ali A Khan, Muhammad A Zahid, Sheharyar Zameer

Abstract readCase Reports
In one paragraph

Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Taimoor A KhanOphthalmology, National University of Medical Sciences (NUMS) Rawalpindi, Rawalpindi, PAK.
Muhammad Zeshan SadiqGeneral Medicine, Military Hospital Rawalpindi, Rawalpindi, PAK.
Ali A KhanInternal Medicine, Ayub Medical College, Abbottabad, PAK.
Muhammad A ZahidOphthalmology, Monash Health, Clayton, AUS.
Sheharyar ZameerGeneral Surgery, Fauji Foundation Hospital, Rawalpindi, PAK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ocular myasthenia gravis (OMG) is a neuromuscular disease characterized by the production of autoantibodies against post-synaptic proteins at the neuromuscular junction (NMJ). An 18-year-old male who had symptoms of drooping eyelids and double vision was diagnosed with ocular myasthenia gravis on investigations and examinations. Treatment was initiated with a tablet of pyridostigmine 60 mg twice daily per oral for two weeks, followed by three times daily for four weeks. The patient demonstrated significant improvement in ptosis and diplopia. There are still a considerable number of challenges in the diagnosis and treatment of ocular myasthenia gravis, with the typical treatment involving acetylcholinesterase inhibitors and immunosuppressants.

Indexed as

autoimmune diseasesmyasthenia gravisneuromuscular diseasespolyneuropathyseropositivity

Identifiers

PMID39280472
PMCPMC11398882

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.